Algernon Pharmaceuticals Inc. C.AGN

RE:RE:The IPF and Chronic Cough study is now on the back burner.

[BlaineBorg]

Those are just random numbers. They don';t apply to any and all clinical trials. You need only review the Topline data news release. It shows a phase 3 for Ifenprodil could range anywhere from 450 patoents to 1900 patients. Surely the per patient cost for domething like Cancer would likely cost more than COVID-19 or the common cough. 

Algernon Pharmaceuticals Announces Topline Data From its  

The CEO needs to land a partnership deal. Otherwise, a go it alone strategy will dilute the company to the high heavens and the only losers in that scenario is the little guy listening to all the stories being told now soon to be on steroids.

Here's another funny thing the CEO said that makes you wonder how serious he is about this stuff.

CJM: You know, I've said many times over the last couple of months that Algernon is not a COVID company, but if you sort of look at the stock and the trading, I think the COVID story did consume much of the oxygen in the room and has for the last period of time. We'll wait to see what comes of the hard work we put in and the research we did in Ifenprodil, but Algernon was always more than our investigation of Ifenprodil for COVID, IPF and cough....

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke | 2021-06-16 | Investing News | Stockhouse

The CEO went balls to the wall steering the company to COVID-19 and he now thinks it took all the oxygen out of the room? It's as if he's having an out of body experience (DMT) and doesn't realize he's the one that created the story in the first place. Not only did COVID-19 leap frog over the direly needed IPF and Chronic Cough study, but more importantly COVID-19 drained the coffers.

The CEO's latest interview is a pretty incredible thing to read.

BB